Skip to content

Released Feb 27, 2025, before the open

10-K filed Feb 27, 2025, 58 days after period end · 0001171843-25-001106

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$15.03MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$16,571,000N/M
Operating Cash Flowderived-$9,162,000N/M
Free Cash Flowderived-$9,162,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Net Income-$15.03M-$13.42M-$11.59M-$12.98M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR